{"created":"2023-06-19T11:24:55.183301+00:00","id":5710,"links":{},"metadata":{"_buckets":{"deposit":"f5398072-77b6-4bc2-84f8-b255158df0dc"},"_deposit":{"created_by":1,"id":"5710","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"5710"},"status":"published"},"_oai":{"id":"oai:asahikawa-med.repo.nii.ac.jp:00005710","sets":["7","7:24"]},"author_link":["17871","17875","17872","17870","17878","17877","17879","17876","17874","17873"],"item_5_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-10-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"10","bibliographicPageEnd":"806","bibliographicPageStart":"797","bibliographic_titles":[{"bibliographic_title":"Therapeutics and Clinical Risk Management"}]}]},"item_5_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"PURPOSE:\n\\nThe general dexmedetomidine (DEX) concentration required for sedation of intensive care unit patients is considered to be approximately 0.7 ng/mL. However, higher DEX concentrations are considered to be required for sedation and/or pain management after major surgery using remifentanil. We determined the DEX concentration required after major surgery by using a target-controlled infusion (TCI) system for DEX.\nMETHODS:\n\\nFourteen patients undergoing surgery for abdominal aortic aneurysms (AAA) were randomly, double-blindly assigned to two groups and underwent fentanyl- or remifentanil-based anesthetic management. DEX TCI was started at the time of closing the peritoneum and continued for 12 hours after stopping propofol administration (M0); DEX TCI was adjusted according to the sedation score and complaints of pain. The doses and concentrations of all anesthetics and postoperative conditions were investigated.\nRESULTS:\n\\nThroughout the observation period, the predicted plasma concentration of DEX in the fentanyl group was stable at approximately 0.7 ng/mL. In contrast, the predicted plasma concentration of DEX in the remifentanil group rapidly increased and stabilized at approximately 2 ng/mL. The actual DEX concentration at 540 minutes after M0 showed a similar trend (0.54±0.14 [fentanyl] versus 1.57±0.39 ng/mL [remifentanil]). In the remifentanil group, the dopamine dose required and the duration of intubation decreased, and urine output increased; however, no other outcomes improved.\nCONCLUSION:\n\\nThe DEX concentration required after AAA surgery with remifentanil was three-fold higher than that required after AAA surgery with fentanyl or the conventional DEX concentration for sedation. High DEX concentration after remifentanil affords some benefits in anesthetic management.","subitem_description_type":"Abstract"}]},"item_5_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"This articles under a Creative Commons Attribution Non-Commercial license (CC-BY-NC).","subitem_description_type":"Other"}]},"item_5_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"text","subitem_description_type":"Other"}]},"item_5_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_5_relation_24":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2147/TCRM.S67211","subitem_relation_type_select":"DOI"}}]},"item_5_source_id_22":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1176-6336","subitem_source_identifier_type":"ISSN"}]},"item_5_text_44":{"attribute_name":"ID(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"23528935"}]},"item_5_text_54":{"attribute_name":"閲覧数(XooNIps)","attribute_value_mlt":[{}]},"item_5_text_55":{"attribute_name":"ダウンロード数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"962"}]},"item_5_text_7":{"attribute_name":"著者 ローマ字","attribute_value_mlt":[{"subitem_text_value":"Kunisawa, Takayuki"},{"subitem_text_value":"Fujimoto, Kazuhiro"},{"subitem_text_value":"Kurosawa, Atsushi"},{"subitem_text_value":"Nagashima, Michio"},{"subitem_text_value":"Matsui, Koji"},{"subitem_text_value":"Hayashi, Dai"},{"subitem_text_value":"Yamamoto, Kunihiko"},{"subitem_text_value":"Goto, Yuya"},{"subitem_text_value":"Akutsu, Hiroaki"},{"subitem_text_value":"Iwasaki, Hiroshi"}]},"item_5_version_type_38":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"国沢, 卓之"},{"creatorName":"クニサワ, タカユキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"藤本, 一弘"},{"creatorName":"フジモト, カズヒロ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"黒澤, 温"},{"creatorName":"クロサワ, アツシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"長島, 道生"},{"creatorName":"ナガシマ, ミチオ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"松井, 康二"},{"creatorName":"マツイ, コウジ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"林, 大"},{"creatorName":"ハヤシ, ダイ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"山本, 邦彦"},{"creatorName":"ヤマモト, クニヒコ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"後藤, 祐也"},{"creatorName":"ゴトウ, ユウヤ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"阿久津, 弘明"},{"creatorName":"アクツ, ヒロアキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"岩崎, 寛"},{"creatorName":"イワサキ, ヒロシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-07-06"}],"displaytype":"detail","filename":"6775.pdf","filesize":[{"value":"443.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"6775.pdf","url":"https://asahikawa-med.repo.nii.ac.jp/record/5710/files/6775.pdf"},"version_id":"abb9a043-43e6-4187-9e11-f63f087203f2"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"abdominal aortic aneurysms (AAA)","subitem_subject_scheme":"Other"},{"subitem_subject":"dopamine","subitem_subject_scheme":"Other"},{"subitem_subject":"effect-site concentration (ESC)","subitem_subject_scheme":"Other"},{"subitem_subject":"plasma concentration","subitem_subject_scheme":"Other"},{"subitem_subject":"target-controlled infusion (TCI)","subitem_subject_scheme":"Other"},{"subitem_subject":"urine output","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article"}]},"item_title":"The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU."}]},"item_type_id":"5","owner":"1","path":["6","7","24"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-09-06"},"publish_date":"2017-09-06","publish_status":"0","recid":"5710","relation_version_is_last":true,"title":["The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-06-19T12:14:40.685762+00:00"}